Role of Microsatellite Instability as Pan-Cancer Agnostic Marker of Solid Tumours in Personalized Medicine-Reference-Cited by-同舟云学术

Role of Microsatellite Instability as Pan-Cancer Agnostic Marker of Solid Tumours in Personalized Medicine

Published:2024-02-12 Issue:3 Volume:5 Page:69-77
ISSN:2662-4079
Container-title:Current Tissue Microenvironment Reports
language:en
Short-container-title:Curr. Tissue Microenviron. Rep.

Author:

Kaler Amrit Kaur^ORCID,Fatima Sheereen,Dhurat Omkar,Rane Samrudhi,Limaye Shweta,Umarji Smitha,Tiwarekar Yash,Nikam Ankita,Kulkarni Bijal,Athikari Nevitha,Shaikh Imran,Goyle Sandeep,Mulchandani Manoj,Kulkarni Yogesh,Mistry Rajesh

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s43152-024-00054-5.pdf

Reference36 articles.

1. Mishima S, Taniguchi H, Akagi K, et al. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. Int J Clin Oncol. 2020;25:217–39.

2. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–56.

3. Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther. 2018;189:45–62.

4. Bansidhar BJ, Silinsky J. History and pathogenesis of lynch syndrome. Clin Colon Rectal Surg. 2012 Jun;25(2):63–6.

5. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9.